BioMimetix will be attending JPM 2024 in San Francisco January 8-10. We recently completed a randomized Phase 2 clinical trial in newly diagnosed High Grade Glioma patients has which demonstrated a 6.6 month increase in Overall Survival in patients treated with BMX-001 + SOC. We are looking for partners as we get ready for our Phase 3 pivotal trial in HGG. Please send us a message to set up a meeting.
